DIRS.INFO The most relevant business & tech news

☆ Cramer's Lighting Round: 'I'm not going to recommend' Altria
▼ + stars: | 2024-11-14 | by ( Julie Coleman | ) www.cnbc.com time to read: +1 min

Stock Chart Icon Stock chart icon Altria's year-to-date stock performance. Stock Chart Icon Stock chart icon Boeing's year-to-date stock performance. Stock Chart Icon Stock chart icon Becton Dickinson's year-to-date stock performance. Stock Chart Icon Stock chart icon IDEAYA Biosciences' year-to-date stock performance. Stock Chart Icon Stock chart icon AstraZeneca's year-to-date stock performance.

Persons: I'm, Becton, Becton Dickinson, Robert F, Kennedy Jr Organizations: Boeing, HHS, Biosciences, IDEAYA Biosciences, AstraZeneca

☆ Here are Tuesday's biggest analyst calls: Nvidia, Tesla, Microsoft, Wells Fargo, Disney, Apple, First Solar & more
▼ + stars: | 2024-10-08 | by ( Michael Bloom | ) www.cnbc.com time to read: +7 min

"We reiterate our Overweight rating on the name as NVDA remains our Top Pick." JPMorgan reiterates Charles Schwab as overweight JPMorgan raised its price target on the stock to $86 per share from $78. "We are initiating coverage of Morningstar (MORN) with a Buy rating and a $390 price target. Wells Fargo reiterates Tesla as underweight Wells says it remains "skeptical" heading into Tesla's robotaxi day later this week. "We are initiating coverage of MBX Biosciences with an Overweight rating and Dec 2025 price target of $30."

Persons: Cantor Fitzgerald, Cantor, TD Cowen, Cowen, Wolfe, Wells, Bernstein, Oppenheimer, Goldman Sachs, Milton, Irma, JPMorgan, Charles Schwab, Morningstar, Redburn, Goldman, Tesla, TSLA, Key, Affirm's, it's, Morgan Stanley, it's bullish, Abbott, Susquehanna, KeyBanc Organizations: Anheuser Busch InBev, InBev, Humana, STARS, Microsoft, Disney, JPMorgan, UBS, Biotech, Legend Biotech, Barclays, Optimus, Qualcomm, Express, American Express, Netflix, Bicara Therapeutics, Abbott Labs, Howmet Aerospace, Commercial Aerospace & Defense, Bank of America, Apple, MBX Biosciences, Delta, Argus, McDonald's Corp Locations: China, Wells Fargo, F4Q17, 1H26, Tesla's

☆ Citi gives its top picks for clients heading into the fourth quarter
▼ + stars: | 2024-10-03 | by ( Sean Conlon | ) www.cnbc.com time to read: +3 min

As the fourth quarter gets underway, there are some stocks that may be poised to outperform over the next several months, according to Citi. "Now, broadening is apparent, with Value leading while Growth has not yet achieved July levels," Scott Chronert said in a Friday note to clients. Citi views newly added Ally Financial as "one of the best-positioned liability sensitive names," seeing the potential for total book value growth of 25% by the fourth quarter of next year. "While mistakes were clearly made with the '22 auto vintage, the short duration of this asset class implies ALLY will not be stuck with the problem beyond 2025," analyst Keith Horowitz wrote. Meanwhile, Citi has a buy rating on the stock, and its price target of $50 implies nearly 45% upside from Wednesday's close.

Persons: Scott Chronert, Keith Horowitz, Horowitz, Ally, Stephen Trent, Filippo Falorni Organizations: Citi, Nasdaq, Dow Jones, North America, Biosciences, Alnylam Pharmaceuticals, Ally, United Airlines, United

☆ Here are Tuesday's biggest analyst calls: Nvidia, Apple, Walmart, Salesforce, Starbucks, Amazon & more
▼ + stars: | 2024-09-24 | by ( Michael Bloom | ) www.cnbc.com time to read: +8 min

Here are Tuesday's biggest calls on Wall Street: Piper Sandler initiates Colgate-Palmolive and Church & Dwight as overweight Piper said both consumer products company offer an attractive risk/reward. Piper Sandler upgrades Salesforce to overweight from neutral Piper said it sees an attractive risk/reward for the stock. Bernstein reiterates Amazon as outperform Bernstein said advertising is "key to the bull case once again" for Amazon. Wedbush upgrades Comerica to outperform from neutral The firm added the regional bank to its best ideas list. " CFRA reiterates Nvidia as buy The firm says it sees Nvidia with "sustained compute demand" over the coming years.

Persons: Piper Sandler, Dwight, Piper, Baird, Jefferies, it's bullish, Raymond James reinstates Uber, Raymond James, Goldman Sachs, Goldman, KeyBanc, Morgan Stanley, immuno, Oppenheimer, Lowe's, Redburn, it's, Truist, Baird downgrades McKesson, Needham, Apple, Pinterest, Leerink, Guggenheim, Tesla, TSLA, Bernstein, CFRA Organizations: Colgate, Palmolive, Church, Jefferies, Starbucks, Avidity Biosciences, BP, Exxon, Costco, Walmart, Apple, GE Vernova, UBS, Citi, Mastercard, Visa, U.S, DOJ, Comerica, CMA, Nvidia

☆ Goldman sees this biotech fighting rare diseases rallying 35%
▼ + stars: | 2024-09-24 | by ( Alex Harring | ) www.cnbc.com time to read: +1 min

Analyst Corinne Johnson initiated coverage of the biopharmaceutical stock focused on unique diseases at a buy rating. "Our positive view of the company is based on what we view as multi-blockbuster, first-to-market commercial opportunities ... coupled with the scalable nature of the company's antibody oligonucleotide conjugate platform," Johnson wrote to clients. The first is del-brax, a drug designed to fight facioscapulohumeral muscular dystrophy, or FSHD — which has estimated peak sales of $2.7 billion. The other is del-desiran, a therapy to treat myotonic dystrophy type 1, or DM1 — with a predicted peak sale figure of $4 billion. Shares have soared more than 380% in 2024, reversing course after dropping more than 59% last year.

Persons: Goldman Sachs, Corinne Johnson, Johnson, what's Organizations: Avidity Biosciences, LSEG Locations: Monday's

☆ Swallowed eels escape via predator fish’s gills
▼ + stars: | 2024-09-13 | by ( Mindy Weisberger | ) edition.cnn.com time to read: +6 min

Dark sleeper fish (Odontobutis obscura) can gulp down young Japanese eels (Anguilla japonica) whole, but the swallowed eels can wriggle back up through the digestive tract and out of the stomach, swimming to freedom through the bigger fish’s gills, scientists recently discovered. “Witnessing the eels’ desperate escape from the predator’s stomach to the gills was truly astonishing for us.”A Japanese eel exhibits circling behavior along a predator's stomach wall in this X-ray video footage. But while they observed swallowed eels wriggling tailfirst from dark sleepers’ gills, “we had no understanding of their escape routes and behavioral patterns during the escape because it occurred inside the predator’s body,” Hasegawa said via email. Once a predator swallowed an eel, the sated fish was quickly moved to a special tank where the X-ray video camera was ready to roll. On average, it took about 3 ½ minutes for a swallowed eel to reappear and swim away.

Persons: ”, Yuha Hasegawa, Yuuki Kawabata, ichthyologist Kory Evans, “, ” Evans, ’ Hasegawa, Kazuki Yokouchi, Nagasaki University —, ” Hasegawa, Prosanta, Mindy Weisberger Organizations: CNN, Graduate School of Fisheries, Environmental Sciences, Japan’s Nagasaki University, “, biosciences, Rice University, Japan Fisheries Research, Education Agency, Nagasaki University, Louisiana State University, LSU Museum of Natural Science, Scientific Locations: Anguilla, Houston

☆ Stocks making the biggest moves after hours: Adobe, RH, Oracle and more
▼ + stars: | 2024-09-12 | by ( Hakyung Kim | In Hakyungkim | ) www.cnbc.com time to read: +1 min

Adobe issued a fiscal fourth-quarter revenue forecast in a range between $5.50 billion and $5.55 billion. Guidance for adjusted earnings per share came in at $4.63 to $4.68 per share, while analysts had expected $4.67 in earnings per share. Oracle — The cloud software company advanced nearly 6% after raising its revenue guidance. RH — The home furnishings company surged nearly 19% after posting a top- and bottom-line beat for the fiscal second quarter. RH reported adjusted earnings of $1.69 per share on $830 million in revenue.

Persons: Adobe, LSEG, —, RH, Kevin Clark, Nick Wells Organizations: Oracle, Neurocrine Biosciences, Aptiv, —, U.S . Securities, Exchange Commission

☆ Goldman says with all the focus on large- and small-caps, you’re missing an opportunity in the middle
▼ + stars: | 2024-09-11 | by ( Hakyung Kim | In Hakyungkim | ) www.cnbc.com time to read: +2 min

Don't get caught up in the debate on large-cap versus small-cap stocks — the real Goldilocks opportunity lies in mid-cap stocks, according to Goldman Sachs. "Today, mid-cap equities offer investors superior earnings growth at a reasonable price compared with large-caps," Ma wrote in a Tuesday note. "Mid-cap stocks have typically outperformed both large-caps and small-caps during the 12 months following the first Fed rate cut in an easing cycle," she added. In addition, mid-caps have "stronger fundamentals" compared with small-cap names, Ma noted. Here are some of Ma's favorite mid-cap names that are both high quality with potential to grow.

Persons: Goldman Sachs, Russell, Jenny Ma, Ma, Ma's Organizations: Neurocrine Biosciences, BioMarin Pharmaceutical

☆ Here are Tuesday's biggest analyst calls: Apple, Costco, Nvidia, Palantir, Broadcom, Tesla, Amazon, Meta & more
▼ + stars: | 2024-09-10 | by ( Michael Bloom | ) www.cnbc.com time to read: +5 min

"We launch coverage of GE Aerospace with an Outperform rating, target price $201." (ELF) with a Buy rating and a 12-month price target of $175 per share." "We initiate with a Buy rating on Harmony , a commercial stage biotech focused on CNS [central nervous system] disorders." "We are initiating coverage of ProKidney Corp. (PROK) with a BUY rating and $6 price target." We are initiating coverage with a BUY rating and $600 price target."

Persons: Morgan Stanley, Apple, Tesla, it's, Bernstein, Riley, Wolfe, Stryker, BUD, JMP, Redburn, BTIG, Palantir, Goldman Sachs, Nutrien, Goldman, Cantor Fitzgerald, Cantor, Melius, Johnson, Guggenheim, it's bullish, D.A, Davidson, Meta Organizations: Apple, Apple Intelligence, Intelligence, Deutsche Bank, Deutsche, GE Aerospace, GE, Inc, Anheuser, Busch InBev, Oracle, Costco, Equity, Haemonetics, Plasma Solutions, Blood Center, Hospital Care Solutions, " Bank of America, Bank of America, UBS, Amazon, Harmony Biosciences, NTR, Nvidia, Broadcom, Johnson, Johnson Controls, ProKidney Corp

☆ Merck beats earnings expectations, raises sales outlook on strong demand for top drugs like Keytruda
▼ + stars: | 2024-07-30 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

Merck on Tuesday reported second-quarter revenue and adjusted earnings that topped Wall Street's expectations as it saw strong sales from its blockbuster cancer drug Keytruda as well as other treatments in its oncology and vaccines portfolios and a newly launched cardiovascular drug. The pharmaceutical giant also raised its full-year sales forecast to a range of $63.4 billion to $64.4 billion on increased demand for key products, particularly its oncology treatments. That's only slightly higher than the $63.1 billion to $64.3 billion guidance the company provided in April. Merck reported $16.11 billion in revenue for the quarter, up 7% from the same period a year ago. Some analysts expect that worldwide sales of Winrevair could reach $5 billion by 2030.

Persons: Keytruda, Merck Organizations: Merck, Harpoon Therapeutics, LSEG, Prometheus Biosciences Locations: Rahway , New Jersey, U.S

☆ Komodo dragons have iron-tipped teeth, new study shows
▼ + stars: | 2024-07-24 | by ( Jack Guy | ) edition.cnn.com time to read: +3 min

London CNN —Komodo dragons, the world’s largest species of lizard, have iron-tipped teeth that help them to rip their prey apart, according to new research. Komodo dragons are native to Indonesia and weigh around 80 kilograms (176 pounds) on average. LeBlanc analyzed teeth from museum collections as well as from a Komodo dragon named Ganus, which lived at London Zoo until it was euthanized last year. Analysis showed that iron was already present when the teeth erupted from the gum tissue, and was also present despite Ganus having a very different diet to wild Komodo dragons, he added. The findings may help us understand how carnivorous dinosaurs, which had curved, serrated teeth similar to Komodo dragons, would have killed and eaten their prey, LeBlanc said.

Persons: Charlotte Ellis, Aaron LeBlanc, LeBlanc, ” LeBlanc, ”, “, Ganus, Benjamin Tapley Organizations: London CNN, Zoological Society of London, King’s College London, CNN, King’s College London “, London Zoo Locations: London, Indonesia

☆ Here are Monday's biggest analyst calls: Nvidia, Apple, Tesla, Microsoft, Amazon, Advanced Micro Devices and more
▼ + stars: | 2024-07-15 | by ( Michael Bloom | ) www.cnbc.com time to read: +7 min

Morgan Stanley reiterates Apple as overweight Morgan Stanley raised its price target on the iPhone maker to $273 per share from $216. Morgan Stanley downgrades BP to equal weight from overweight Morgan Stanley downgraded the oil major due to "weak earnings." Morgan Stanley reiterates Microsoft as overweight Morgan Stanley said it has "increased clarity" on AI monetization. Citi names KLA Corp. a top pick Citi raised its price target on the semiconductor equipment maker to $980 from $760. Morgan Stanley downgrades Rocket Lab to equal weight from overweight Morgan Stanley said it sees a "limited catalyst path" for the space company.

Persons: Morgan Stanley, Apple, Morgan Stanley downgrades, TD Cowen, Teck, Baird, CARR, Zeta, John Donovan, AAPL, Wells, Tesla, underperform Wells, it's, Evercore, it's bullish, DDOG Organizations: Netflix, Nvidia, Devices, AMD, Citi, Electronic Arts, College Football, BMO, Teck Resources, JPMorgan, Biosciences, Zeta Global, Citi downgrades Bank of New York Mellon, Bank, New York Mellon, Apple, IOL, Amazon, UW, CIO, Susquehanna, Caesars, MGM, PENN, Bank of America, KLA Corp, OW, Department of Defense Locations: 2H24, Dell, Teck, TSLA, Las Vegas

☆ Stocks making the biggest moves midday: Intuit, AMD, LegalZoom.com, Baidu and more
▼ + stars: | 2024-07-10 | by ( Sean Conlon | ) www.cnbc.com time to read: +4 min

In terms of revenue, LegalZoom now expects between $675 million and $685 million for the full year. Taiwan Semiconductor Manufacturing — The chip stock advanced 3% following the company's revenue results . Though the company's reported T$207.87 billion for the month of June was a 9.5% decrease from last month, it was a 32.9% increase from the year-ago period. For January through June this year, the company reported T$1.27 trillion, which is a 28% increase from the same period last year. Carvana — Shares of the online car seller added 5% after Needham upgraded the stock to buy from hold.

Persons: LegalZoom.com, Dan Wernikoff, Jeffrey Stibel, LegalZoom, Carvana, Needham, robotaxi, —, Alex Harring, Fred Imbert, Samantha Subin, Pia Singh, Michelle Fox, Darla Mercado Organizations: Intuit —, Intuit, Taiwan Semiconductor Manufacturing, Baidu, Street Journal, Shanghai, Mastercard, Visa, Bank of America, Manchester United, BioSciences, Analysts, Illumina, Teva Pharmaceutical Industries, Argus, UBS, Science, AMD, Silo Locations: China, Shanghai, Hoka, Europe

☆ Stocks making the biggest moves midday: Paramount Global, Morphic Holding, Ideaya Biosciences and more
▼ + stars: | 2024-07-08 | by ( Sean Conlon | ) www.cnbc.com time to read: +3 min

Skydance and its financial backers will invest more than $8 billion into Paramount and to acquire National Amusements, Paramount's controlling shareholder. Morphic Holding – Shares rallied 75% on news that Eli Lilly will acquire the biopharmaceutical company in a $3.2 billion deal . The deal will give Eli Lilly access to Morphic's portfolio of treatments in development, such as those for ulcerative colitis and Crohn's disease. Shares of Eli Lilly advanced 1.3% on the news. Boeing – Shares fell slightly after the airplane maker agreed to plead guilty to criminal fraud related to the fatal 737 Max crashes, sparing Boeing from a trial.

Persons: Eli Lilly, BofA, Corning, Guggenheim, Max, Grayson, Raymond James, Samantha Subin, Pia Singh, Hakyung Kim, Sarah Min, Michelle Fox Organizations: Paramount Global, Skydance Media, Skydance, Paramount, National, Morphic, Ideaya Biosciences, Bank of America, Boeing –, Boeing, ., CNBC, Devon Energy, Gilead Sciences Locations: Columbia, Stifel, Williston, Gilead

☆ Stocks held by ARK Invest's flagship innovation fund have seen huge losses. Here are the fund's 10 biggest losers.
▼ + stars: | 2024-05-27 | by ( Matthew Fox | ) www.businessinsider.com time to read: +3 min

Ark Invest's flagship innovation ETF, which trades under the ticker symbol "ARKK," has seen massive losses since it peaked in February 2021. Here are the 10 biggest losers held in the ARKK ETF, according to data from Cathie's Ark. Pacific BiosciencesMarkets InsiderARKK average cost basis: $19.84Current price: $1.88% Change: -90.2%2. Teladoc HealthMarkets InsiderARKK average cost basis: $163.91Current price: $11.43% Change: -93.0%Advertisement1. Ginkgo BioworksMarkets InsiderARKK average cost basis: $9.99Current price: $0.66% Change: -93.4%

Persons: —, It's, Wood, Tesla Organizations: ARK, Service, Invest, Nasdaq, Intellia Therapeutics, UiPath, Roku, Verve Therapeutics, Unity Technologies, Genomics, Pacific Biosciences, Teladoc

☆ Generative AI will be designing new drugs all on its own in the near future
▼ + stars: | 2024-05-05 | by ( Trevor Laurence Jockims | ) www.cnbc.com time to read: +12 min

An analogy for understanding the development of AI drugs can be found in the mechanisms of ChatGPT. As a result, it's a drug discovery process that has a 90% failure rate. Some of the noted flaws of generative AI, its propensity to "hallucinate" for example, could prove to be powerful in drug discovery. AI is learning to distinguish drugs from non-drugs, and to create new drugs, in the same way that ChatGPT can create sentences, Ellington said. Now, AI models are helping narrow down the possibilities, so scientists more quickly know the optimal modifications to try.

Persons: ChatGPT, Kimberly Powell, Google's, —, AlphaFold, Powell, Rau, Lilly, Eli Lilly, Diogo Rau, It's, Amgen, Andy Ellington, Ellington, Daniel Diaz, Diaz, We've Organizations: Nvidia, CNBC Technology, Summit, University of Texas, Austin, NVIDIA, biosciences, UT's Institute, Foundations of Machine, Cadence Locations: Nature

☆ Stocks making the biggest moves midday: Apple, Expedia, Block, Live Nation and more
▼ + stars: | 2024-05-03 | by ( Hakyung Kim | ) www.cnbc.com time to read: +3 min

Check out the companies making headlines in midday trading: Apple — The tech giant jumped more than 6% after announcing it would repurchase $110 billion in shares . That topped analysts' estimates for earnings of $1.50 per share on revenue of $90.01 billion, per LSEG. Block — The payment services provider added 1% after posting first-quarter results that beat analysts' expectations. Live Nation Entertainment — Shares jumped 9% on the back of better-than-expected first-quarter revenue. However, the company beat analysts' expectations for the first quarter.

Persons: LSEG, Piper Sandler, FactSet, Eli Lilly, Cloudflare, Jefferies, —, Alex Harring, Lisa Kailai Han, Michelle Fox, Pia Singh Organizations: Apple, Management, Wall Street, BMO Capital Markets, Expedia, Holdings, bullish Bank of America, Novo Nordisk, Arista Networks, Arista Locations: Thursday's, billings

☆ This rare muscle disease play can rally more than 50%, BofA says
▼ + stars: | 2024-05-03 | by ( Alex Harring | ) www.cnbc.com time to read: +2 min

Avidity Biosciences stock has more room to run thanks to the company's pipeline of multiple treatments for rare muscle disorders, according to Bank of America. Avidity has a therapeutic platform — antibody oligonucleotide conjugates — that was well-received at the time it went public in 2020, Meacham said. But shares were hurt by a clinical hold on Avidity's leading program for treating an uncommon muscle disorder, DM1. The program, tested in the Marina trial, recently saw long-term data that has "helped lift that key overhang on the stock," Meacham said. Those catalysts are tied to two other drugs in the muscle disorder space that are expected to report data this year, according to Meacham.

Persons: Geoff Meacham, Meacham Organizations: Biosciences, Bank of America Locations: San Diego, Thursday's

☆ Here are Friday's biggest analyst calls: Apple, Target, Coinbase, Berkshire Hathaway, Estee Lauder & more
▼ + stars: | 2024-05-03 | by ( Michael Bloom | ) www.cnbc.com time to read: +6 min

JPMorgan upgrades Williams-Sonoma to neutral from underweight JPMorgan said in its upgrade of the stock that the home furnishings category is stabilizing. "We are downgrading shares of EXPE to Mkt Perform from OP with a target price of $145 vs. $165 previously." JPMorgan upgrades Joby to neutral from underweight JPMorgan said its bear thesis has largely played out for the aviation company. Guggenheim reiterates Target as buy Guggenheim said investors should buy the dip in shares of Target . Morgan Stanley downgrades Estee Lauder to equal weight from overweight Morgan Stanley said it sees a slower recovery for shares of Estee Lauder .

Persons: Stifel, Wells, Truist, OLLI, Guggenheim, Tim Cook, William Blair, Amgen, Jefferies, We've, Ari sta, it's, Morgan Stanley downgrades Estee Lauder, Morgan Stanley, Estee Lauder, TD Cowen, Parsons, Bernstein, Oppenheimer, CFRA, Berkshire Hathaway Organizations: RBC, FTAI Aviation, Pacific, Union Pacific, JPMorgan, Williams, WSM, BMO, Bank of America, Apple, Kiniksa Pharmaceuticals, JOBY, Guggenheim, Target, Citi, MCW, Arista, PSN, Avidity, ~$ Locations: Sonoma, EXPE, GEICO

☆ A longevity researcher is facing backlash for claiming to 'reverse aging.' Scientists say there's no consensus on what it means.
▼ + stars: | 2024-04-28 | by ( Lakshmi Varanasi | ) www.businessinsider.com time to read: +4 min

Read previewHarvard researcher Dr. David Sinclair has found himself at the center of controversy within the longevity community. He's also earned his share of critics who say his research isn't always backed up by sufficient evidence. Animal Biosciences reissued a press release walking back the "reverse aging" claim. But scientists in the field say the issue is even more fundamental: There's no way to reverse aging, much less measure it. That means debates about the semantics of aging will only become more relevant to our daily lives.

Persons: —, David Sinclair, Sinclair, He's, Dr, Nir Barzilai, Matt Kaeberlein —, Matt Kaeberlein, Barzilai, it's, it'll, Andrea Maier, Jeff Bezos, Peter Thiel Organizations: Service, Business, Street Journal, Animal Biosciences, Newsweek, The Academy for Health, Academy for Health, Academy, National Institute, Aging, MIT Technology, National University of Singapore, Longevity

☆ Wells Fargo becomes bullish on this biotech company
▼ + stars: | 2024-04-24 | by ( Hakyung Kim | ) www.cnbc.com time to read: +1 min

Neurocrine Biosciences ' drug pipeline is turning a corner and the company will be "knocking on the doors of the large-cap club" soon, according to Wells Fargo. Bansal forecasts the company's congenital adrenal hyperplasia treatment, crinecerfont, will achieve $1.5 billion in peak sales, topping his prior $1.1 billion estimate. "We think [the] Crinecerfont [opportunity] is underappreciated as the Street is only giving credit for $500-$700M peak opportunity." Bansal said this drug could open "a whole new chapter" of a $1.2 billion peak sales opportunity. The NBI-'845 treatment could be "another blockbuster opportunity," Bansal said, citing the treatment's once-daily administration as a factor in his assessment.

Persons: Mohit, Bansal, Takeda, — CNBC's Michael Bloom Organizations: Biosciences Locations: Wells Fargo

☆ How R&D Funding Is Making the UK a Global Leader in Science
▼ + stars: | 2024-04-17 | by ( Sponsor Post | ) www.businessinsider.com time to read: +8 min

Exscientia's growth was bolstered by government support: The company didn't take venture funding until 2019. Exscientia wouldn't be where it was, Taylor said, without the support of the UK higher education system and government funding. Martin Tangney, the chief scientific officer of Edinburgh-based Celtic Renewables, said the £11 million of funding his company received in 2015 from the UK government was "pivotal." Advertisement"We really believe … [that] basically, soon all drugs are going to be created with AI," Taylor said. AdvertisementClick here to find out more about how your business can benefit from Research & Development in the UK.

Persons: Ben Taylor, Achilles, Taylor, —, We've, Smith, Nephew, we've, Martin Tangney, isn't, ABE, you've, Tangney Organizations: Nasdaq, University of Dundee, AstraZeneca, COVID, Celtic Renewables, biosciences, Department for Science, Innovation & Technology, Edinburgh Napier University, Government, Renewables, Research & Development, Insider Studios, UK's Department for Business & Trade, Innovation, Technology Locations: Oxford, UK, Edinburgh, Scotland, Ireland, Japan, America, India, Grangemouth

Morgan Stanley raised its price target on Nvidia, calling for more than 15% upside going forward. — Lisa Kailai Han 5:53 a.m.: Jefferies lowers Tesla price target, cites 'self-inflicted' wounds Tesla's troubles may not be over yet, according to Jefferies. The investment firm kept its hold rating on the electric vehicle maker and lowered its price target to $165 from $185. Jefferies analyst Philippe Houchois also said Tesla is plagued by shifting product priorities. — Lisa Kailai Han 5:53 a.m.: Morgan Stanley raises Nvidia price target Nvidia has already rallied more than 72% in 2024.

Persons: Morgan Stanley, Jefferies, Patrick Cunningham, Erik Fyrwald's, Cunningham, — Lisa Kailai Han, Zillow, John Colantuoni, Colantuoni, Scott Schoenhaus, Schoenhaus, Lisa Kailai Han, Hess, Betty Jiang, CVX, Jiang, Tesla, Philippe Houchois, Joseph Moore, Moore, — Fred Imbert Organizations: CNBC, Nvidia, Citi, Management, & Biosciences, Jefferies, National Association of Realtors, Markets, GDRX, Barclays, Chevron, NVIDIA, AMD Locations: Tuesday's, China

☆ Record levels of funding propel Denver-Boulder to the top of the life sciences market
▼ + stars: | 2024-04-08 | by ( Chris Dilella | ) www.cnbc.com time to read: +7 min

The Denver-Boulder region is rapidly emerging as a major hub for the life sciences industry, attracting companies that develop cutting-edge medical treatments and technologies. Life sciences research aims to understand living things, from cells to our planet, to improve health, food and the environment. Founded in 2003, the Bioscience Association supports the growth of life sciences, with a focus on access to capital, education, networking and more. A recent CBRE report found Denver-Boulder to be the top U.S. life sciences real estate market, fueled by record investment from venture capitalists and the National Institutes of Health. Entrepreneurial successThe recent surge in venture capital flowing into Denver-Boulder builds on the area's proven track record of success over the past several decades.

Persons: Tim Schoen, BioMed, Schoen, Elyse Blazevich, Kevin Koch, Koch, Edgewise, We've, Dan LaBarbera, LaBarbera, Dr Organizations: BioMed, CNBC, Blackstone, Flatiron, Enveda Biosciences, Denver, Boulder, Colorado Bioscience Association, Bioscience Association, National Institutes of Health, U.S, Pfizer, Therapeutics, University of Colorado, Edgewise Therapeutics, Research, University of Colorado's Anschutz Medical, Center, Drug, Center for Drug, for Drug, Anschutz Medical Locations: CNBC's, Denver, Boulder, Diego, Boulder , Colorado, San Diego, San Francisco, Seattle, Boston, Cambridge, Massachusetts, Aurora, Rocky, Colorado, Boulder ., Denver's

☆ Sam Altman's mission to increase human lifespan with a $180 million shipping container experiment at Retro Biosciences
▼ + stars: | 2024-03-23 | by ( Hilary Brueck | ) www.businessinsider.com time to read: +11 min

Called Retro Biosciences, the startup's goal is simple yet supremely ambitious: Add 10 healthy, enjoyable years onto the back end of our lifetimes. But Retro Biosciences actually fits quite neatly into Altman's futuristic worldview. Retro BiosciencesRetro Biosciences sits about 30 miles south of OpenAI's San Francisco headquarters, where ChatGPT was hatched. Joe Betts-LaCroix is the CEO of Retro Biosciences. There are things we already know work super well to improve human longevity, like exercise, diet, faith, and social support.

Persons: Sam Altman, he's, Elon Musk, Mark Zuckerberg, Altman, Instacart —, Joe Betts, LaCroix, isn't, Betts, Retro's, spry, Yamanaka, Shinya Yamanaka, it's, they've, Sora, Thiel, Jeff Bezos, Bezos, Yuri Milner, Billionaire Peter Thiel, He's, Aubrey de Grey, Christian Angermayer, biogerontologist Daniel Promislow, Altman's, Matt Buckley Organizations: Business, OpenAI, Biosciences, Harvard, MIT, Caltech, Extension, Apple, Stanford University, Retro, Bezos, Labs, Billionaire, Cambrian, Retro Biosciences, Bloomberg Locations: geroscience, Silicon Valley, OpenAI's San Francisco, Meta, Golden City, Retro.bio, Redwood City , California, San Diego

Search resuls for: "biosciences"

25 mentions found